ReviewWorld journal of clinical cases2023
Liver replacement therapy with extracorporeal blood purification techniques current knowledge and future directions.
Review in World journal of clinical cases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Liver Xenotransplantation: From Early Primate Trials to the First-in-Human Porcine Bridging Therapies.Journal of clinical medicine · 2026Review
- Comparison of the liver support systems OPAL and ALBUNIQUE in critically ill patients with liver dysfunction.The International journal of artificial organs · 2026Article
- Cast nephropathy in the ICU: Early recognition and extracorporeal strategies to improve outcomes.Journal of intensive medicine · 2026Review
- Genistein Supplementation Affects Mineral Homeostasis in Rats with Mammary Cancer.Foods (Basel, Switzerland) · 2026Article
- Extracorporeal hemoperfusion as an adjunctive therapy for liver failure.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2025Article
- Article
- Comparison of Open Albumin Dialysis (OPAL) With Prometheus Fractionated Plasma Separation and Adsorption (FPSA) and Standard Medical Treatment for Acute-On-Chronic Liver Failure.Artificial organs · 2025Article
- Difficult extubation following recovery from acute liver failure: Use of point-of-care critical care assessment.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025Article
- Extracorporeal organ support for critically ill patients: Overcoming the past, achieving the maximum at present, and redefining the future.World journal of critical care medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinically, it is highly challenging to promote recovery in patients with acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). Despite recent advances in understanding the underlying mechanisms of ALF and ACLF, standard medical therapy remains the primary therapeutic approach. Liver transplantation (LT) is considered the last option, and in several cases, it is the only intervention that can be lifesaving. Unfortunately, this intervention is limited by organ donation shortage or exclusion criteria such that not all patients in need can receive a transplant. Another option is to restore impaired liver function with artificial extracorporeal blood purification systems. The first such systems were developed at the end of the 20
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.